JVM Co (054950) Fair Value & Analysis
Healthcare · KR · Market cap 260B KRW
Fair value as of: Jun 25, 2026
Analysis
JVM Co (054950) currently trades at 20,950 KRW, while our model-based Fair Value estimate is 41,845 KRW — implying the stock looks roughly 99.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
JVM Co., Ltd. develops and sells automation systems and software of dispensing, packaging, and medication management for hospitals and pharmacies worldwide. It offers automatic dispensing and packaging systems; medication inspection and winding systems; medicine counting systems; canister management systems; automatic tablet counting systems; automatic tablet cutting systems; automatic PTP deblisters; special shape tablets pre-preparation systems; automatic pouch rolling systems; DOB blister paper sealing guides; and automated medication management systems. The company also provides OnCube Management for dispensing, packaging, and medication management; Check VIZEN, a pouch inspection and management software; STS Load Station, an STS pre-packaging software; INTIPharm Management, a medication management software; INTIPharm Notifier, a medication management alert software; INTIPharm Transfer Check, a medication management transfer software; and INTIPharm Secusion Viewer, a medication …
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is JVM Co (054950) undervalued?
What is the fair value of 054950?
What is the quality score of 054950?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.